[1] 李蕾,韩江莉,李海燕,等.冠心病患者氯吡格雷抵抗与血小板参数的相关分析[J].中华医学杂志,2013,93(12):916. [2] 余长永,张勇,邹建军,等.氯吡格雷抵抗原因及对策的研究进展[J].中国临床药理学与治疗学,2009,14(10):1168-1173. [3] Gurbel PA,Bliden KP,Hiatt B1,et al. Clopidogrel for coronary stenting: response variability drug resistance end the effect of pretreatment platelet reactivity [J].Circulation,2003,107(23):2908. [4] 谢媛,马向华.抗血小板药物抵抗的研究进展[J].医学综述,2012,18(20):3366. [5] 王明亮,朱毅,甘洁民.急性冠脉综合症患者中氯吡格雷抵抗的发生率及影响因素[J].中国临床药学杂志,2010,19(3):144. [6] Hall HM,Baneoee S,McGuire DK.Variability of elopidogrel response in patients with type 2 diabetes mellitus[J].Diab Vasc Dis Res,2011,8(4):245-253. [7] E1 Ghannudi S,Ohlmann P,Jesel L,et al. Impaired inhibition of P2Y12 by elopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention[J].Atherosclerusis,2011,217(2):465-472. [8] Vizioli L,Muscari S,Muscafi A.The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases[J].Int J Clin Pract,2009,63(10):1509-1515. [9] Lance MD,Slocp M,Henskens YM,et a1.Mean platelet volume as a diagnostic marker for cardiovascular disease:drawbacks of preanalytical conditions and measuring techniques[J].Clin Appl Thromb Hemost,2012,18(6):561-568. |